These findings, repeated in many laboratories, kindled the hope that agonists that elicit a fluid and secretory response via non-CFTR channels may alleviate the disease manifestations of patients with cystic fibrosis in the different epithelia affected by the disease [7]. The gene discussed is CFTR; the disease is cystic fibrosis.